ArticleCancer medicine2023
The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Measurable residual disease detected by next-generation sequencing in T-cell acute lymphoblastic leukemia.Nature communications · 2026Article
- Non-specific Clones Hamper the Reliability of Immunoglobulin Light Chain Gene Rearrangements in Next-Generation Sequencing-Based Measurable Residual Disease Monitoring in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Center Cohort Study.Annals of laboratory medicine · 2026Observational
- Next-Generation Sequencing for Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia: Technological Advances, Clinical Translations and Current Challenges.Current issues in molecular biology · 2026Review
- The effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia.Stem cell research & therapy · 2026Article
- Validation of an Adapted NGS-Based Clonality Assay for MRD Monitoring in B-ALL Using Archived and Follow-Up Samples.EJHaem · 2025Article
- Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.Cancer medicine · 2025Observational
- Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry.Annals of hematology · 2025Article
- Immunoglobulin NGS enhance residual disease detection and prognosis in pediatric Ph+ acute lymphoblastic leukemia.Frontiers in immunology · 2025Article
- Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.Blood cancer journal · 2024Article
- Article
- Blinatumomab in the Therapy of Acute B-Lymphoid Leukemia.Mediterranean journal of hematology and infectious diseases · 2024Review
- The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBlinatumomab improved survival outcomes in B-cell acute lymphoblastic leukemia (B-ALL) patients with measurable residual disease (MRD) <10
methodsPatients (n = 19) whose MRD was undetectable by multiparameter flow cytometry (MFC) (sensitivity of 10
resultsAfter one course of blinatumomab, 13/19 patients (68%) successfully achieved NGS-MRD clearance (undetectable). With a median follow-up of 13.3 months, three of patients who were NGS-MRD positive relapsed within 1.8 months, while another three remained complete remission.
conclusionsOur study was the first to demonstrate that blinatumomab could further eradicate MRD after patients achieve MFC-MRD undetectable in B-ALL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.